Skip to Content

Tag: RemSleep


Also Noted

RemSleep receives OTCQB status

July 13, 2022HME News Staff

TAMPA, Fla. – RemSleep Holdings has received approval to be uplisted to OTCQB status with otcmarkets.com. “This is a great milestone for RemSleep and our shareholders,” said Tom Wood, CEO. “We could not be more excited for where we are currently positioned and the trajectory of where we are going. Uplisting to OTCQB status provides next level accountability from us as a company with higher reporting standards and more comprehensive compliance requirements.” RemSleep...

RemSleep, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

RemSleep seeks OTCQB status 

June 14, 2022HME News Staff

TAMPA, Fla. – RemSleep has officially filed its application for OTCQB status with otcmarkets.com and expects to receive a decision in about three to four weeks. The company believes the move to the OTCQB will provide enhanced investor benefits, including higher reporting standards, greater access to analyst coverage and news outlets, and more comprehensive compliance requirements. The U.S. Securities and Exchange Commission considers the OTCQB an “established public market” for...

RemSleep


Read Full Articlered right arrow icon

Also Noted

RemSleep applications advances

May 10, 2022HME News Staff

TAMPA, Fla. – RemSleep Holdings says it has responded to the Additional Information request related to its 510(k) application to the U.S. Food and Drug Administration for its patented DeltaWave nasal mask CPAP interface. “This submission is expected to be the final step and pivotal moment for our company,” said CEO Tom Wood. “It will dramatically strengthen the commercialization of our brand and make the DeltaWave a premier product that reinforces our commitment to providing...

CPAP, DeltaWave, RemSleep


Read Full Articlered right arrow icon

Also Noted

REMSleep provides update on DeltaWave 

March 29, 2022HME News Staff

TAMPA, Fla. – REMSleep has engaged a new third-party lab to redo testing for its DeltaWave as part of the 510k process for the nasal CPAP interface. The company says it has received a negative result on a cytotoxicity test due to incorrect procedures performed by a previous lab and has failed a re-test due to a faulty analysis by a testing company. “The failed test is not a result of management; we have run into a problem that we had not anticipated,” said CEO Tom Wood. “While...

CPAP Device, CPAP interface, DeltaWave, RemSleep


Read Full Articlered right arrow icon

Also Noted

RemSleep engages investor relations firm, news service

January 25, 2022HME News Staff

TAMPA, Fla. – RemSleep Holdings has partnered with Preya Co. and MCAP Mediawire to maximize its communication and exposure with current and potential shareholders, as well as refine and broaden its overall messaging and outreach. The move comes as the company prepares to get its DeltaWave nasal CPAP interface approved by the U.S. Food and Drug Administration and launched to market. “We feel we owe it to our current and future investors to have partnered with a gold star firm to assist...

nasal interface, RemSleep, Sleep Apnea


Read Full Articlered right arrow icon